Oscient Pharmaceuticals (OSCI) 8-K Oscient Pharmaceuticals Releases Preliminary Results from Phase II

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 10, 2004

OSCIENT PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts	0-10824	04-2297484
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

(781) 398-2300

(Registrant’s telephone number, including area code)

Page 1 of 4 pages.

ITEM 5.    OTHER EVENTS

On August 10, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing the completion of its Phase II clinical trial of Ramoplanin for the treatment ofClostridium difficile-associated diarrhea, which is attached hereto as Exhibit 99.1.

ITEM 7.    FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

        99.1 Press Release issued by Oscient Pharmaceuticals Corporation on August 10, 2004.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OSCIENT PHARMACEUTICALS CORPORATION
By:	/s/    Stephen Cohen
	Name: Stephen Cohen Title: Senior Vice President and Chief Financial Officer

Date: August 10, 2004

3

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued by Oscient Pharmaceuticals Corporation on August 10, 2004.

4